Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.
about
European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemiaDasatinib-loaded albumin nanoparticles possess diminished endothelial cell barrier disruption and retain potent anti-leukemia cell activityA critical role for Lyn kinase in strengthening endothelial integrity and barrier function.TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targetsFirst-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies.Management of adverse events associated with tyrosine kinase inhibitors in chronic myeloid leukemia.Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.Chronic myeloid leukemia: Second-line drugs of choice.Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia.Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.ABL tyrosine kinase inhibitor-induced pulmonary alveolar proteinosis in chronic myeloid leukemia.Rho-Kinase Inhibition Ameliorates Dasatinib-Induced Endothelial Dysfunction and Pulmonary Hypertension.
P2860
Q26749324-C77B1C23-BD29-4A73-B520-9DC41E628A87Q28468632-6FE8F324-889A-41C0-8BBC-656A66E7B9D7Q37390244-1C1268CD-7A3C-4834-88ED-220DF94AD2D9Q37509428-7107AE5B-1C3D-43A2-9F4C-616B03344A92Q38202913-D51A00A2-0D2A-46CC-86E7-E7FBEE9CA3C2Q38392679-93A5F319-8210-4D80-A433-E3B93207623BQ38457554-B3639586-95CE-49FF-AF94-7464D4F448F4Q38640422-2D14471F-5CF0-4956-9D0E-0F13F90C2B29Q39186183-6C21769F-AB35-453C-8490-6446415E5F3FQ47877989-80E4A750-343B-40A7-865D-D60FA2C05FF3Q51698195-9EE89C12-FB53-4E3C-9002-AAD28582CB9EQ54977070-C808A01E-F1F7-4DE1-BDD8-EA7D64D81DD1
P2860
Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Incidence, risk factors and ma ...... chronic myelogenous leukaemia.
@en
Incidence, risk factors and ma ...... chronic myelogenous leukaemia.
@nl
type
label
Incidence, risk factors and ma ...... chronic myelogenous leukaemia.
@en
Incidence, risk factors and ma ...... chronic myelogenous leukaemia.
@nl
prefLabel
Incidence, risk factors and ma ...... chronic myelogenous leukaemia.
@en
Incidence, risk factors and ma ...... chronic myelogenous leukaemia.
@nl
P2093
P2860
P50
P356
P1476
Incidence, risk factors and ma ...... chronic myelogenous leukaemia.
@en
P2093
Alessandra Iurlo
Antonella Gozzini
Carmen Fava
Dario Ferrero
Elisabetta Calistri
Francesco Cavazzini
Giuseppe Visani
Isabella Capodanno
Luigiana Luciano
Mario Annunziata
P2860
P304
P356
10.1002/HON.2020
P50
P577
2012-07-19T00:00:00Z